| | GAITHERSBURG, Md., Feb. 29, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in TD Cowen’s 44th Annual Health Care Conference. | Conference Details: | | | | Fireside Chat | | | Date: | Wednesday, March 6, 2024 | | Time: | 1:30 – 2:00 p.m. Eastern Standard Time (EST) | | Location: | Boston Marriott Copley Place in Boston, Massachusetts | | Moderator: | Brendan Smith, Ph.D., Vice President, Biotechnology Equity Research | | Novavax participant: | John Jacobs, President and Chief Executive Officer | | | | | | Conference | | | Event: | Investor Meetings | | Date: | Wednesday, March 6, 2024 | About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax’s patented Matrix-M adjuvant to enhance the immune response. The Company’s portfolio includes its COVID-19 vaccine and its pipeline includes a vaccine for COVID-19 and influenza combined. In addition, Novavax’s adjuvant is included in the University of Oxford and Serum Institute of India’s R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information. Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com Media
Ali Chartan
240-720-7804
media@novavax.com  View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-td-cowens-44th-annual-health-care-conference-302076367.html
SOURCE Novavax, Inc. | |
